Investment Summary

Eisai Invests In C2N Diagnostics

On March 6, 2024, Eisai invested in life science company C2N Diagnostics

Investment Highlights
  • This is Eisai’s 2nd transaction in the Life Science sector.
  • This is Eisai’s 2nd transaction in the United States.
  • This is Eisai’s 1st transaction in Missouri.

Investment Summary
Date 2024-03-06
Target C2N Diagnostics
Sector Life Science
Investor(s) Eisai
Deal Type Growth Capital

Target

C2N Diagnostics

St. Louis, Missouri, United States
website
C2N provides clinical laboratory services and advanced diagnostic solutions in the field of brain health. The company's high-resolution mass spectrometry-based biomarker services and products are used for clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N is based in St. Louis, Missouri.

Search 193,092 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Eisai

Woodcliff Lake, New Jersey, United States

website

Category Company
Founded 1995
Sector Life Science
DESCRIPTION

Eisai, Inc. is a pharmaceutical company focuses on neurology, gastrointestinal disorders and oncology/critical care.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Growth Capital) 1 of 1
State (Missouri) 1 of 1
Country (United States) 2 of 2
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-04-01 Eisai - Two Medicines

Woodcliff Lake, New Jersey, United States

Eisai, Inc. - Two Medicines (Salagen & Panretin) is a pharmaceutical business, Salagen® indications include the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck, and the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome. Panretin® indications include the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma (KS).

Sell $33M
Mergr

Product

Company

Legal